Claims
- 1. A compound of the structure
- 2. The compound of claim 1, which is 2,2′,2″-nitrilotrisethyl trisbutyrate or a pharmaceutically acceptable salt thereof.
- 3. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 4. The pharmaceutical composition of claim 3, wherein said compound is is 2,2′,2″-nitrilotrisethyl trisbutyrate or a pharmaceutically acceptable salt thereof.
- 5. The compound of the structure
- 6. The compound of claim 5, which is 2-(4-morpholinyl)ethyl butanamide.
- 7. A pharmaceutical composition, comprising a compound of claim 5 and a pharmaceutically acceptable carrier or diluent.
- 8. The pharmaceutical composition of claim 7, wherein said compound is 2-(4-morpholinyl)ethyl butanamide or a pharmaceutically acceptable salt thereof.
- 9. The compound of the structure
- 10. The compound of claim 9, which is 2-(4-butanoylpiperazinyl)ethyl butanoate.
- 11. A pharmaceutical composition, comprising a compound of claim 9 and a pharmaceutically acceptable carrier or diluent.
- 12. The pharmaceutical composition of claim 11, wherein said compound is 2-(4-butanoylpiperazinyl)ethyl butanoate or a pharmaceutically acceptable salt thereof.
- 13. The compound of structure
- 14. The compound of claim 13, which is 1-methyl-4-piperidinyl butanoate.
- 15. A pharmaceutical composition, comprising a compound of claim 13 and a pharmaceutically acceptable carrier or diluent.
- 16. The pharmaceutical composition of claim 15, wherein said compound is 1-methyl-4-piperidinyl butanoate or a pharmaceutically acceptable salt thereof.
- 17. A method of inactivating antigen-specific T cells in a n individual in need of such treatment, comprising the step of administering to said individual an effective amount of a compound of structure
- 18. The method of claim 17, wherein said compound is 2,2′,2″-nitrilotrisethyl trisbutyrate or a pharmaceutically acceptable salt thereof.
- 19. The method of claim 17, wherein inactivation of antigen-specific T cells is useful in the prophylaxis or therapeutic treatment of autoimmune diseases, disorders involving an autoimmune component or neoplastic diseases.
- 20. The method of claim 19, wherein said autoimmune diseases are selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, diabetes, and multiple sclerosis.
- 21. The method of claim 19, wherein said disorders involving an autoimmune component are selected from the group consisting of allograft transplantation rejection and xenograft transplantion rejection.
- 22. The method of claim 19, wherein said neoplastic disease is selected from the group consisting of renal cancer, ovarian cancer, lung cancer, glioma and leukemia.
- 23. A method of inactivating antigen-specific T cells in an individual in need of such treatment, comprising the step of administering to said individual an effective amount of a compound of structure
- 24. The method of claim 23, wherein said compound is 2-(4-morpholinyl)ethyl butanamide or a pharmaceutically acceptable salt thereof.
- 25. The method of claim 23, wherein said compound is 2-(4-morpholinyl)ethyl butanoate or a pharmaceutically acceptable salt thereof.
- 26. The method of claim 23, wherein inactivation of antigen-specific T cells is useful in the prophylaxis or therapeutic treatment of autoimmune diseases, disorders involving an autoimmune component or neoplastic diseases.
- 27. The method of claim 26, wherein said autoimmune diseases are selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, diabetes, and multiple sclerosis.
- 28. The method of claim 26, wherein said disorders involving an autoimmune component are selected from the group consisting of allograft transplantation rejection and xenograft transplantion rejection.
- 29. The method of claim 26, wherein said neoplastic disease is selected from the group consisting of renal cancer, ovarian cancer, lung cancer, glioma and leukemia.
- 30. A method of inactivating antigen-specific T cells in an individual in need of such treatment, comprising the step of administering to said individual an effective amount of a compound of structure
- 31. The method of claim 30, wherein said compound is 2-(4-butanoylpiperazinyl)ethyl butanoate or a pharmaceutically acceptable salt thereof.
- 32. The method of claim 30, wherein inactivation of antigen-specific T cells is useful in the prophylaxis or therapeutic treatment of autoimmune diseases, disorders involving an autoimmune component or neoplastic diseases.
- 33. The method of claim 30, wherein said autoimmune diseases are selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, diabetes, and multiple sclerosis.
- 34. The method of claim 30, wherein said disorders involving an autoimmune component are selected from the group consisting of allograft transplantation rejection and xenograft transplantion rejection.
- 35. The method of claim 30, wherein said neoplastic disease is selected from the group consisting of renal cancer, ovarian cancer, lung cancer, glioma and leukemia.
- 36. A method of inactivating antigen-specific T cells in an individual in need of such treatment, comprising the step of administering to said individual an effective amount of a compound of structure
- 37. The method of claim 36, wherein said compound is 1-methyl-4-piperidinyl butanoate or a pharmaceutically acceptable salt thereof.
- 38. The method of claim 36, wherein inactivation of antigen-specific T cells is useful in the prophylaxis or therapeutic treatment of autoimmune diseases, disorders involving an autoimmune component or neoplastic diseases.
- 39. The method of claim 36, wherein said autoimmune diseases are selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, diabetes, and multiple sclerosis.
- 40. The method of claim 36, wherein said disorders involving an autoimmune component are selected from the group consisting of allograft transplantation rejection and xenograft transplantion rejection.
- 41. The method of claim 36, wherein said neoplastic disease is selected from the group consisting of of renal cancer, ovarian cancer, lung cancer, glioma and leukemia.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of priority of U.S. provisional patent application Serial No. 60/136,579, filed May 28, 1999, now abandoned.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60136579 |
May 1999 |
US |
Divisions (2)
|
Number |
Date |
Country |
Parent |
10122277 |
Apr 2002 |
US |
Child |
10734919 |
Dec 2003 |
US |
Parent |
09579602 |
May 2000 |
US |
Child |
10122277 |
Apr 2002 |
US |